Scientific Reports (Jan 2025)

Plasma levels of anti phosphocholine IgM antibodies are negatively correlated with bone mineral density in humans

  • Michela Palmieri,
  • Spyridoula Maraka,
  • Horace J. Spencer,
  • Jeff D. Thostenson,
  • Katherine Dishongh,
  • Micheal Knox,
  • Betty Ussery,
  • Jesse Byrd,
  • Jacqueline K. Kuipers,
  • Sanaz Abedzadeh-Anaraki,
  • Chitharanjan Duvoor,
  • Yuanjie Mao,
  • Lakshmi Menon,
  • James S. Williams,
  • Stavros C. Manolagas,
  • Robert L. Jilka,
  • Elena Ambrogini

DOI
https://doi.org/10.1038/s41598-025-85624-9
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Phosphatidylcholine is a ubiquitous phospholipid. It contains a phosphocholine (PC) headgroup and polyunsaturated fatty acids that, when oxidized, form reactive oxidized phospholipids (PC-OxPLs). PC-OxPLs are pathogenic in multiple diseases and neutralized by anti-PC IgM antibodies. The levels of anti-PC IgM increase as the levels of PC-OxPLs increase and, in humans, are inversely correlated with the incidence of cardiovascular diseases and steatohepatitis. PC-OxPLs also decrease bone mass in mice. Overexpression of anti-PC IgM ameliorates atherosclerosis and steatohepatitis, increases bone mass in young mice, and protects against high fat diet- and age-associated osteoporosis. We investigated the relationship between anti-PC IgM plasma levels and bone mineral density (BMD) in a cross-sectional study of 247 participants [mean age: 65.5 (± 8.6) years] without medical conditions known to influence BMD or antibody production. Anti-PC IgM levels negatively correlated with both T- and Z-scores at the lumbar spine, femur and, to a lesser extent, the forearm. These correlations were maintained after adjustment for age, race, and sex. These results raise the possibility that higher levels of anti-PC IgM in patients with lower BMD reflect exposure to higher levels of PC-OxPLs, which are known to affect bone mass, and could be a novel risk marker for osteoporosis.

Keywords